Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Welcome The Hill’s annual list of Top Lobbyists. President Trump’s return to the White House brought a whirlwind of policy ...

Once construction is complete in 2032, the company plans on creating some of its "biggest medicines" at the new facility.

Health-care companies fell as traders weighed risks in a wave of deal activity. Pfizer joined Big Pharma rivals hunting for novel weight loss drugs in the Chinese biotech sector.

Dow Jones Top Company Headlines at 5 PM ET: JPMorgan Stock Sinks on Higher Expense Outlook. Other Banks May Have to Keep Up. | Nvidia ... JPMorgan Stock Sinks on Higher Expense Outlook. Other Banks ...

The executive, who would expand the size of the board to a total of 11 members, will stand election at the media giant's 2026 annual meeting of shareholders ...

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

Jeff Williams, a former Apple executive, will stand for election as a new independent director of Disney at the 2026 annual ...

Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...